Interní Med. 2016; 18(5): 233-235 | DOI: 10.36290/int.2016.053
Therapy of nonalcoholic steatohepatitis (NASH)
- 1 II. interní gastroenterologická klinika, FN Hradec Králové
- 2 I. interní kardioangiologická klinika, FN Hradec Králové
Incidence of nonalcoholic steatohepatitis as a part of non-alcoholic fatty liver disease is still increasing and NASH and its complications are becoming one of the most common indications for liver transplantation. Screening of NASH in high risk subgroups and its diagnosis is still difficult with a need of liver biopsy. Management of NASH is based on lifestyle intervention, diet and weight loss. Cornerstone of pharmacotherapy is the treatment of associated diabetes, arterial hypertension and dyslipidemy and there is an indication for the treatment with vitamin E and pioglitazon in some patients. The prospective randomised trials with some new promising drugs are still ongoing and result are awaited.
Keywords: steatohepatits, nonalcoholic, therapy
Published: December 1, 2016 Show citation
References
- Chalasani N, et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6): 2005-2023.
Go to original source... 
Go to PubMed... - Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6): 1387-1395. Go to original source... Go to PubMed...
- Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). J Clin Gastroenterol. 2004; 38(10): 891-897. Go to original source... Go to PubMed...
- Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol 2015; 62: S47-64. Go to original source... Go to PubMed...
- Goh GB, Pagadala MR, Dasarathy J, el al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 2015; 35(3): 979-985. Go to original source... Go to PubMed...
- Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011; 106(3): 460-468. Go to original source... Go to PubMed...
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2): 367-378. Go to original source... Go to PubMed...
- Shen H, Rodriguez AC, Shiani A, et al. Association between caffeine consumption and non-alcoholic fatty liver disease: a systemic review and meta-analysis. Ther Adv Gastroenterol 2016; 9(1): 113-120. Go to original source... Go to PubMed...
- Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010; 362: 1675-1685. Go to original source... Go to PubMed...
- Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387(10019): 679-690. Go to original source... Go to PubMed...
- Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011; 306(14): 1549-1556. Go to original source... Go to PubMed...
- Neuschwander-Tetri BA, Loomba R, Sanyal AJ. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385(9972): 956-965. Go to original source... Go to PubMed...
- Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011; 54(5): 1011-1019. Go to original source... Go to PubMed...
- Du J, Ma YY, Yu CH, et al. Effects of pentoxifylline on non-alcoholic fatty liver disease: a meta-analysis. World J Gastroenetrol 2014; 20(2): 569-577. Go to original source... Go to PubMed...
- Ratziu V, Goodman Z, Sanyal AJ. Current efforts and trends in the tratment of NASH. J Hepatol 2015; 62: S65-75. Go to original source... Go to PubMed...